We report the in vitro antibiotic susceptibility of 1,220 strains belonging to the thermotolerant Campylobacter species, isolated from the feces of pediatric patients with diarrhea in the period from 1987 to 1993. The strains were identified as 1,148 C.jejuni isolates and 72 C. coli isolates. The overall results show that the strains showed drug resistance as follows: 51.8% to ampicillin, 4.4% to clindamycin, 2.6% to chloramphenicol, 21.2% to tetracycline, and 1% to gentamicin. Twenty-one strains (1.7%) displayed resistance to the combination of amoxicillin-clavulanic acid, and 3.2% of the strains were resistant to erythromycin (MIC of .4 ,ug/ml), with a notable diference according to the species under consideration. While C. jejuni remained stable at 0.9 to 4% resistance to erythromycin, for C. coli the percentages detected ranged from 0 to 33%, with overall rates of 2.5 and 15.2% for the two species, respectively. Resistance to nalidixic acid (MIC of .32 ,ug/ml) was found in 27.2% of the strains (27.8% for C. jejuni and 18% for C. col), and resistance to ciprofloxacin (MIC of .4 ,Ig/ml) was found in 24.2% of the strains for C. jejuni and 15.2% for C. coli). Cross-resistance between nalidixic acid and ciprofloxacin was found in 89.1% of the strains (type 1 mutants), while 10.9% were resistant to nalidixic acid but susceptible to ciprofloxacin (type 2 mutants).
The thermotolerant Campylobacter species (C. jejuni and C. coli) are among the principal causes of infantile diarrhea (3, 23) . Although the majority of these clinical processes are self-limiting and do not require specific antibiotic treatment, it is, nevertheless, necessary to know the antibiotic susceptibility of this bacterial group to be able to choose the correct therapy in those cases in which the severity of the disease or the patient's condition does require such therapy (10, 20) . It is therefore necessary to ascertain the susceptibilities of these species to the antimicrobial agents recommended for the treatment of diarrhea.
The aim of this work was the study of antimicrobial susceptibilities of the Campylobacter strains isolated from the feces of pediatric patients with diarrhea in the period from 1987 to 1993 and to ascertain the development of resistance to the principal groups of antimicrobial agents.
In the period from 1987 to 1993, we studied the in vitro susceptibilities of 1,220 strains belonging to species of thermotolerant Campylobacter to 10 different antimicrobial agents. All strains had been isolated from the feces of pediatric patients with diarrhea, following routine protocol, which consists of the use of selective Campylosel agar (bioMerieux) incubated at 42°C for 48 h. Biochemical species identification was performed by means of the hippurate and indoxyl acetate hydrolysis tests, growth in the presence of 1.5% NaCl, H2S production in TSI medium, pigment production, and susceptibility to cephalothin (30 ,ug) and nalidixic acid (30 p,g) (11) .
The antimicrobial agent susceptibility study was performed by using the agar diffusion method in plates of Mueller-Hinton agar with 5% sheep's blood incubated in a microaerophilic atmosphere for 24 h. We used disks of ampicillin (10 ,ug), amoxicillin-clavulanic acid (30 ,ug) , clindamycin (10 ,ug) , chloramphenicol (30 ,ug) , tetracycline (30 ,g), gentamicin (10 ,ug) , and imipenem (10 ,ug) (Oxoid Ltd.). Erythromycin and the fluoroquinolones (nalidixic acid and ciprofloxacin) were studied by both the agar diffusion method and the broth dilution method in order to establish the MICs (expressed in micrograms per milliliter). For this purpose we used 15-,ug discs of erythromycin, 30-,ug discs of nalidixic acid, and 5-,ug discs of ciprofloxacin (Oxoid Ltd.) Table 1 ). The antimicrobial agent susceptibility study included only 1,148 strains of C. jejuni and 72 of C. coli.
As shown in Table 2 , of the C. jejuni strains 51.4% were resistant to ampicillin and 1.8% were resistant to the combination of amoxicillin-clavulanic acid. In 1992, two strains were resistant to imipenem and six strains (2.2%) were resistant to gentamicin. Resistance to erythromycin has shown a progressive increase to 4% in 1993, although the overall resistance rate was 2.5%.
Of the C. jejuni strains studied during this period, there was a striking increase in resistance to nalidixic acid, from 2.3% in 1988 to 55.2% in 1993 (P of <0.005), and to ciprofloxacin, from 2.3% in 1988 to 48.8% in 1993 (P of <0.005) ( Table 2 ). The overall rates of resistance to nalidixic acid and ciprofloxacin for this species were 27.8 and 24.8%, respectively. In the last 4 years, the presence of strains resistant to nalidixic acid but susceptible to ciprofloxacin has been observed, with an increase from 4% in 1991 to 11.4% in 1993 (P of <0.005).
Of the C. coli strains, it is worth noting that 58.3% show (21) , however, showed important differences in resistance percentages according to the species tested. Thus, while no strain of C. jejuni displayed resistance, 10% of the C. coli strains did. In our study, the overall percentage of resistance to chloramphenicol was 2.6%, although, unlike the strains studied by Sagara et al. (21) , C. jejuni showed the highest resistance rate. Resistance to this antibiotic is brought about by the production of the chloramphenicol acetyl transferase enzyme, which is encoded on a transferable plasmid (21, 25) . Therefore, resistance percentages may vary in different geographical areas, according to the incidence of this plasmid.
Campylobacter resistance to the tetracyclines is determined by a conjugative plasmid present in more than 80% of strains for which the MICs are >25 ,ug/ml (26, 27, 29, 30) . The rates of resistance to this antibiotic vary between 0 and 69% (6, 31), with certain variations according to species. Sagara et al. (21) reported that 60% of C. coli strains display resistance, as opposed to 30% of C. jejuni strains. Our study also showed differences in the percentages of resistance between the two species, with 21.6% for C. jejuni versus 15.2% for C. coli.
In general, erythromycin has been considered the antibiotic of choice for the treatment of diarrhea caused by Campylobacter strains, especially in infants. The resistance percentages reported for this antibiotic vary widely according to geographical zones, although, in general, they range from 1 to 10% in developed countries (1, 24, 32) . Taylor et al. (28) reported erythromycin resistance rates of 11 and 53% for C. jejuni and 46 and 91% for C. coli, in Thailand, according to whether the origin of the strain was the community or closed institutions, respectively. The overall resistance rate detected previously by us was 3.2% (18, 19) . This value has remained almost stable for C. jejuni and increased for C. coli in 1989 and 1990 to 33%, only to decrease in 1991 to 14.8%. This gives results of 2.5% for C. jejuni and 15.2% for C. coli (P of <0.005).
Our percentages of resistance to erythromycin confirm that the species C. coli is much more resistant to this antibiotic than C. jejuni. This fact had been observed previously by Wang et al. (33) and confirmed by Taylor et al. (28) and other investigators who demonstrated that the strains of C. coli isolated in pigs were those with the highest resistance rate, close to 70% (33) . This phenomenon may be due to the indiscriminate use of the macrolide antibiotic tylosin (analogous to erythromycin) for fattening these animals, which would lead to the appearance of strains with cross-resistance to erythromycin, which would subsequently be ingested by humans (2) . Studies concerning the antibiotic susceptibilities of Campylobacter strains performed up to 1987 had shown that strains resistant to the fluoroquinolones were practically nonexistent (4, 5, 12, 13) . The introduction of ciprofloxacin and norfloxacin for clinical use led to the appearance of an increasing number of strains with resistance to these antimicrobial agents. The parallel inclusion of enrofloxacin in veterinary practice appears to have reinforced the process (4) . In 1988, we detected the first three strains of C. jejuni resistant to all quinolones studied, with an overall resistance rate of 2.3% (16) . In 1989, we observed a slight increase in the incidence of resistance to 3.4% (15) . Rather more striking, however, was the increase in resistance to nalidixic acid detected in 1990 (19%), which reached 55% in 1993. Nevertheless, the overall rate detected for all strains studied was 27.2%. Until 1991, we failed to detect any C. coli strain with resistance to nalidixic acid (17) . In that year the resistance rate was 29.6% for this species and 18% for all strains studied.
Until 1989, resistance to nalidixic acid in C. jejuni strains was invariably crossed with resistance to ciprofloxacin (type 1 mutants) (34) . In 1990, however, we found that only 68.8% of nalidixic acid-resistant strains were also resistant to ciprofloxacin, and in 1993, of the strains resistant to nalidixic acid, only 88.5% were also ciprofloxacin resistant. Of the total 1,220 strains studied, 10.9% (10.7% of the C. jejuni strains and 15.4% of the C. coli strains) may be considered type 2 mutants because of their phenotypic behavior (14, 34) .
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